{
    "Trade/Device Name(s)": [
        "DRI Tricyclics Serum Tox Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K213875",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983268"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFH"
    ],
    "Summary Letter Date": "December 21, 2022",
    "Summary Letter Received Date": "August 23, 2022",
    "Submission Date": "August 19, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.3910"
    ],
    "Regulation Name(s)": [
        "Tricyclic antidepressant drugs test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Tricyclic antidepressants",
        "Nortriptyline",
        "Amitriptyline",
        "Imipramine",
        "Desipramine",
        "Clomipramine",
        "Dosulepin",
        "Doxepin",
        "Lofepramine",
        "N-Desmethyltrimipramine",
        "Norclomipramine",
        "Nordoxepin",
        "Opipramol",
        "Protriptyline",
        "Trimipramine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "K2 EDTA tube",
        "K3 EDTA tube",
        "Lithium Heparin tube",
        "Sodium Citrate tube",
        "Potassium Oxalate tube",
        "Sodium Heparin tube",
        "Other standard serum or urine collection containers"
    ],
    "Instrument(s)/Platform(s)": [
        "Architect c4000 clinical chemistry analyzer",
        "Other clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Enzyme activity spectrophotometry at 340 nm"
    ],
    "Methodologies": [
        "Enzyme immunoassay (EIA)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Tricyclics Serum Tox Assay, a homogeneous enzyme immunoassay for detecting tricyclic antidepressants in serum, plasma, or urine.",
    "Indications for Use Summary": "Homogeneous enzyme immunoassay for qualitative and/or semiquantitative determination of tricyclic antidepressants in human serum, plasma, or urine at 300 ng/mL cutoff in patients suspected of drug overdose; for preliminary analytical results with confirmatory testing recommended.",
    "fda_folder": "Toxicology"
}